Abstract:Programmed cell death 1 (PD-1) is an inhibitory receptor expressed on a variety of immune cells and a therapeutic target of checkpoint immunotherapy for cancer patients. PD-1 engagement by PD-L1 or PD-L2 can inhibit activation and expansion of tumor antigen-specific T cells. PD-1 expression in tumor-associated macrophages (TAM) correlates with impaired phagocytosis and antigen presenting function and enhanced immunosuppression. PD-1 is also expressed in dendritic cells (DC) and has been shown to correlate negatively with the outcome of DC-based cancer vaccines. On DC, PD-1 can interact with PD-L1 in cis when both of these receptors are expressed on the same cell surface. DCs are the major antigen presenting cells for cross-presenting tumor antigens to T cells, and PD-L1 upregulation protects them from killing by cytotoxic T lymphocytes, yet dampens the antitumor responses. Very little is known about the specific role of PD-1 on DCs function. In the present study, we sought to understand the role of PD-1 on DCs in the context of cancer. We generated mice with conditional targeting of the Pdcd1 gene (encoding for PD-1) and crossed them with CD11cCre ( Pdcd1 f/fCD11cCre) or Clec9Cre ( Pdcd1 f/fClec9Cre) resulting in specific deletion of PD-1 in DC cells. We used the MC17 fibrosarcoma syngeneic mouse model to investigate the tentative implications of DC-specific PD-1 ablation on anti-tumor responses. We found larger tumor sizes and weights in tumor-bearing Pdcd1 f/fCD11cCre mice compared to their Pdcd1 wt/wtCD11cCre control counterparts. Pdcd1 f/fCD11cCre tumor-bearing mice had significantly higher fractions of DCs in spleens and tumor-draining lymph nodes (tdLNs) but only minimal differences in their activation state and checkpoint marker expression. Similarly, CD4 + and CD8 + T cells from spleens and tdLNs were comparable in percentages and activation states. However, characterization of the immune cells at the tumor site, indicated that Pdcd1 f/fCD11cCre tumor-bearing mice had a more immunosuppressive tumor microenvironment with increased fractions of CD11b +Ly6C hiLy6G -monocytic myeloid derived suppressor cells (M-MDSCs) compared to control tumor-bearing mice. Moreover, flow cytometric analysis revealed that intratumoral M-MDSC in Pdcd1 f/fCD11cCre mice displayed enhanced expression of PD-L1 and CD38, consistent with a more activated and more immunosuppressive phenotype. Characterization of tumor infiltrating CD4 + and CD8 + T cells also revealed vast differences in composition and activation states. Specifically, Pdcd1 f/fCD11cCre mice had larger populations of intratumoral CD3 + T cells, with a greater CD4/CD8 T cell ratio, and higher percentages of CD4 + T regulatory cells. Conversely, intratumoral CD8 + T cells were reduced, and were characterized by diminished expansion of CD8 + T effector cells, and a less activated phenotype as determined by lower expression of CD25, CD69, and GITR. In syngeneic tumor experiments with B16 melanoma expressing ovalbumin (B16-Ova), Pdcd1 f/fCD11cCre mice and Pdcd1 f/fClec9Cre mice similarly had greater tumor sizes and weights compared to their control counterparts. These results indicate that selective ablation of PD-1 in DCs cells confers a more immunosuppressive tumor microenvironment by promoting T regulatory cell expansion and diminishing CD8 + T effector cell activation compromising anti-tumor responses.

CBX4 Promotes Antitumor Immunity by Suppressing Pdcd1 Expression in T Cells.

CBX4 suppresses CD8+ T cell antitumor immunity by reprogramming glycolytic metabolism

CBX4 Suppresses Metastasis Via Recruitment of HDAC3 to the Runx2 Promoter in Colorectal Carcinoma.

Cbx4 Regulates the Proliferation of Thymic Epithelial Cells and Thymus Function

New Tumor Suppressor Cxxc Finger Protein 4 Inactivates Mitogen Activated Protein Kinase Signaling

Protein kinase D1 phosphorylates CBX8 to facilitate the disassociation of PRC1 complex from p16 promoter and promotes cell senescence

Role of PDCD4 in Inflammation and Tumors: a Double-Edged Sword

CBX4 deletion promotes tumorigenesis under Kras G12D background by inducing genomic instability

Polycomb Chromobox 4 Enhances Migration and Pulmonary Metastasis of Hepatocellular Carcinoma Cell Line MHCC97L

CBX4 Deletion Promotes Tumorigenesis under KrasG12D Background by Inducing Genomic Instability

Role of Programmed Cell Death 4 in Diseases: a Double-Edged Sword

CCDC134 Facilitates T Cell Activation Through the Regulation of Early T Cell Receptor Signaling.

PD-1 Expression By Dendritic Cells Is a Key Regulator of T-Cell Immunity in Cancer

Cbl-b inhibited CD4+T cell activation by regulating the expression of miR-99a/miR-125b

OCT4B Regulates P53 and P16 Pathway Genes to Prevent Apoptosis of Breast Cancer Cells

Abstract 2244: AKT Activation by Pdcd4 Knockdown Upregulates Cyclin D1 Expression and Promotes Cell Proliferation

Programmed Cell Death 4 Modulates Lysosomal Function by Inhibiting TFEB Translation.

PDCD4 interacting with PIK3CB and CTSZ promotes the apoptosis of multiple myeloma cells

HBx-mediated miR-21 upregulation represses tumor-suppressor function of PDCD4 in hepatocellular carcinoma

CBX4 Provides an Alternate Mode of Colon Cancer Development via Potential Influences on Circadian Rhythm and Immune Infiltration

BCL9 regulates CD226 and CD96 checkpoints in CD8+ T cells to improve PD-1 response in cancer